XML 59 R23.htm IDEA: XBRL DOCUMENT
v3.19.3

Legal Settlements and Loss Contingencies | 9 Months Ended
--- | ---
Sep. 30, 2019
Legal Settlements and Loss Contingencies | NOTE 15 – Legal settlements and loss contingencies: In the third quarter of 2019, Teva recorded an expense of $468 million in legal settlements and loss contingencies, compared to $19 million in the third quarter of 2018. The expense in the third quarter of 2019 was mainly related to an increase in the estimated settlement provision recorded in connection with the remaining opioid cases. In the first nine months of 2019, Teva recorded an expense of $1,171 million in legal settlements and loss contingencies, compared to income of $1,239 million in the first nine months of 2018. The expense in the first nine months of 2019 was mainly related to an estimated settlement provision recorded in connection with the remaining opioid cases. As of September 30, 2019 and December 31, 2018, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $1,601 million and $562 million, respectively.

X
- Definition The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI http://asc.fasb.org/topic&trid=2127136 + Details
Name: | us-gaap_LegalMattersAndContingenciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration